Black Diamond Therapeutics (BDTX) Total Non-Current Liabilities (2018 - 2020)

Black Diamond Therapeutics' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $21.9 million for Q4 2020.

• Quarterly Total Non-Current Liabilities rose 350.59% year-over-year to $21.9 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $21.9 million (up 350.59% YoY) and the FY2020 annual result came in at $21.9 million, up 350.59% from the prior year.
• Total Non-Current Liabilities was $21.9 million for Q4 2020 at Black Diamond Therapeutics, up from $19.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $21.9 million in Q4 2020 and bottomed at $2.6 million in Q4 2018.
• A 3-year average of $10.4 million and a median of $6.9 million in 2020 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2019 — Total Non-Current Liabilities surged 88.85% — and 2020, when it soared 350.59%.
• Black Diamond Therapeutics' Total Non-Current Liabilities stood at $2.6 million in 2018, then jumped by 88.85% to $4.9 million in 2019, then surged by 350.59% to $21.9 million in 2020.
• Business Quant data shows BDTX's Total Non-Current Liabilities at $21.9 million in Q4 2020, $19.1 million in Q3 2020, and $6.3 million in Q2 2020.